Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU, Indian And US Leaders Share Global Outlook To 2030

Association Heads Set Out Views Following Launch Of IGBA ‘Vision’ Whitepaper

Executive Summary

At an IGBA panel discussion moderated by Generics Bulletin’s editor, three industry leaders representing Europe, India and the US debated the key issues facing the international off-patent sector today.

You may also be interested in...



Generics Bulletin Editor’s Picks For Q3 2021

Looking back over a busy third quarter in 2021, Generics Bulletin executive editor David Wallace picks out highlights from July to September that include major legal and regulatory developments, multiple firsts in the biosimilars arena, significant M&A activity and our annual ranking of the off-patent sector’s top 50 companies.

IGBA Sets Out Industry Vision To 2030

A whitepaper setting out a comprehensive vision for the off-patent industry to 2030 has been launched by the IGBA. Highlighting the industry’s current contribution to healthcare, it also sets out a path ahead for the generics and biosimilars sector, pointing out headwinds as well as opportunities.

Entries Begin To Roll In For 2024 Industry Awards

Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB151112

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel